
What doctors want you to know about weight and weight loss
What doctors want you to know about weight and weight loss
Show Caption
Hide Caption
Ozempic warning: Experts warn of side effects from weight loss drug
Experts are warning of the possible side effects of popular diabetes medications such as Ozempic and Mounjaro when used for weight loss.
Weight is an eternally-pressing topic, but conversations around GLP-1s and other weight loss drugs have brought it to the forefront even more.
Body mass index (BMI) is the tool doctors use to calculate whether someone is underweight, at a healthy weight, overweight or obese. But because BMI calculations can't tell the difference between body fat, muscle and bone mass, it's not always the best way to actually tell if a patient is healthy, many medical experts argue.
"We know that muscle weighs more than fat, so their weight may not be a good indicator of how much fat they have in their body," says Dr. Jennifer Brull, president of the American Academy of Family Physicians. "Patients who suffer from being overweight or obese can face stigma. Focusing too much on weight rather than taking a more holistic approach can be detrimental to the care of all patients. Addressing these health risks require a customized, sensitive approach from a family physician."
Here's what medical experts want you to know about being overweight and how it relates to your health.
The fastest way to lose weight? Diets, pills and the conversation we need to have
What is considered overweight?
BMI is calculated using a person's weight and height, with the idea that it can show if a person's weight is healthy based on an estimation of their body fat percentage.
"A BMI that is low could mean a person doesn't have enough body fat. A high BMI could mean that they have too much body fat," Brull says, though she notes that "every body is different and BMI isn't one-size-fits-all."
Per the Centers for Disease Control and Prevention (CDC), these are the BMI categories for adults 20 and older:
Underweight: BMI is less than 18.5
BMI is less than 18.5 Healthy Weight: 18.5 to less than 25
18.5 to less than 25 Overweight: 25 to less than 30
25 to less than 30 Obesity: 30 or greater Class 1 Obesity: 30 to less than 35 Class 2 Obesity: 35 to less than 40 Class 3 Obesity: 40 or greater
30 or greater
Seen this yet? Travis Kelce, Jake Gyllenhaal and why BMI is problematic. It needs to change, panel says.
How to lose weight
Health experts stress that tactics to lose large amounts of weight quickly are either inaccurate or unsustainable.
"There's not a magical food or drink that can help you lose body fat," dietitian Caroline Thomason previously told USA TODAY. "Unfortunately, the boring basics still work for weight loss: Diet and exercise are the two most important factors you can change to lose weight."
For those looking to lose weight, Thomason recommends starting with the following daily lifestyle tweaks:
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Kennedy names 8 vaccine committee replacements, including COVID shot critic
NEW YORK (AP) — U.S. Health Secretary Robert F. Kennedy Jr. on Wednesday named eight new vaccine policy advisers to replace the panel that he abruptly dismissed earlier this week. They include a scientist who researched mRNA vaccine technology and transformed into a conservative darling for his criticisms of COVID-19 vaccines, and a leading critic of pandemic-era lockdowns. Kennedy's decision to 'retire' the previous 17-member panel was widely decried by doctors' groups and public health organizations, who feared the advisers would be replaced by a group aligned with Kennedy's desire to reassess — and possibly end — longstanding vaccination recommendations. The new appointees to the Advisory Committee on Immunization Practices include Dr. Robert Malone, the former mRNA researcher who emerged as a close adviser to Kennedy during the measles outbreak. Malone, who runs a wellness institute and a popular blog, rose to popularity during the COVID-19 pandemic as he relayed conspiracy theories around the outbreak and the vaccines that followed. He has appeared on podcasts and other conservative news outlets where he's promoted unproven and alternative treatments for measles and COVID-19. He has claimed that millions of Americans were hypnotized into taking the COVID-19 shots. He's even suggested that those vaccines cause a form of AIDS. He's downplayed deaths related to one of the largest measles outbreaks in the U.S. in years. Other appointees include Dr. Martin Kulldorff, a biostatistician and epidemiologist who was a co-author of the Great Barrington Declaration, an October 2020 letter maintaining that pandemic shutdowns were causing irreparable harm. Dr. Cody Meissner, a former ACIP member, also was named. Kennedy made the announcement in a social media post on Wednesday. The committee, created in 1964, makes recommendations to the director of the Centers for Disease Control and Prevention. CDC directors almost always approve those recommendations on how Food and Drug Administration-cleared vaccines should be used. The CDC's final recommendations are widely heeded by doctors and determine the scope of vaccination programs. ___ Associated Press reporter Amanda Seitz contributed to this report. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.


CNN
an hour ago
- CNN
HHS reinstates more than 450 CDC employees fired in April reorganization
Federal agencies Health care policyFacebookTweetLink Follow The US Department of Health and Human Services is reinstating more than 450 employees at the US Centers for Disease Control and Prevention who were fired as part of a massive reorganization in April, including workers focused on HIV, lead exposure and workplace safety. More than 200 employees had their firings rescinded at the CDC's National Center for HIV, Viral Hepatitis, STD and Tuberculosis Prevention, along with 158 at the National Center for Environmental Health, an HHS spokesperson confirmed. Another 71 were brought back in the Office of the Director and two dozen more at the Global Health Center. The reinstatements represent almost 20% of the 2,400 CDC employees who HHS said it was dismissing in a mass Reduction in Force, or RIF, in April. The cuts also affected employees across the US Food and Drug Administration, the US National Institutes of Health and the US Centers for Medicare and Medicaid Services, but an HHS spokesperson said Wednesday's reinstatements applied only to employees at the CDC. 'Under Secretary Kennedy's leadership, the nation's critical public health functions remain intact and effective,' HHS Director of Communications Andrew Nixon said in a statement. 'The Trump Administration is committed to protecting essential services – whether it's supporting coal miners and firefighters through NIOSH, safeguarding public health through lead prevention, or researching and tracking the most prevalent communicable diseases. 'HHS is streamlining operations without compromising mission-critical work,' he continued. 'Enhancing the health and well-being of all Americans remains our top priority.' The cuts had wiped out the CDC's Childhood Lead Poisoning Prevention and Surveillance Branch as it was in the midst of helping the city of Milwaukee address a lead exposure crisis in its public schools. The firings meant the CDC had to deny a request from the city for specialists to help.
Yahoo
an hour ago
- Yahoo
Study: Real-world results of GLP-1 drugs don't match trials
Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised by the drugs' clinical trials, a new study says. People taking such GLP-1 drugs lost just under 9% of their body weight on average after a year, researchers reported Tuesday in the journal Obesity. That's far less than the 15% to 21% body weight reduction promised by the clinical trials that led to the approval of Wegovy (semaglutide) and Zepbound (tirzepatide) for weight loss, researchers said. "Patients treated for obesity with semaglutide or trizepatide lost less weight on average in a regular clinical setting compared to what is observed in randomized clinical trial," lead investigator Hamlet Gasoyan said in a news release. He is a researcher at the Cleveland Clinic Center for Value-Based Care Research. People taking the drugs in real-world settings appear to be more likely to quit taking the meds, researchers said. They also might be prescribed lower dosages in clinical practice than were used in the drug trials. Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food. For this study, researchers tracked nearly 7,900 patients being treated by the Cleveland Clinic for severe obesity, of whom about 6,100 were prescribed semaglutide and the rest tirzepatide. Average body weight loss after a year was nearly 9% for the whole group, results show. But weight loss varied based on when a person stopped taking the drugs, researchers found. Average weight loss was under 4% for those who stopped treatment early, versus nearly 7% or those who stopped later on, the study says. Those who stayed on their medications lost an average 12% body weight. Results also show that more than 4 in 5 (81%) of patients were prescribed a low maintenance dose of their GLP-1 drug, and that made a difference as well. People who stayed on their meds and received high doses lost nearly 14% of their body weight with semaglutide and 18% with tirzepatide. "Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of health care providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions," Gasoyan said. Overall, patients had higher odds of losing 10% or more of their body weight after a year if they remained on their meds, were prescribed a high dosage, were taking tirzepatide rather than semaglutide, and were female, results show. The cost of the drugs and problems were insurance were a common reason for patients stopping GLP-1 treatment, along with side effects and medication shortages, researchers said. Staying on the GLP-1 meds particularly helped the nearly 17% of patients who had prediabetes, a condition in which elevated blood sugar levels increase a person's risk of developing Type 2 diabetes. About 68% of those who stuck with their treatment wound up with normal blood sugar levels, compared with 41% who stopped taking the drugs later in the study and 33% who stopped earlier. "Type 2 diabetes is one of the most common complications of obesity, so diabetes prevention is very important," Gasoyan said. "This study highlights that treatment discontinuation, especially early, negatively affects both weight and glycemic control outcomes." A follow-up study is in the works to better track why patients stop taking their GLP-1 drugs, researchers said. More information Harvard Medical School has more on GLP-1 drugs. Copyright © 2025 HealthDay. All rights reserved.